ES1077470U - Container for medicinal products. (Machine-translation by Google Translate, not legally binding) - Google Patents
Container for medicinal products. (Machine-translation by Google Translate, not legally binding) Download PDFInfo
- Publication number
- ES1077470U ES1077470U ES201230722U ES201230722U ES1077470U ES 1077470 U ES1077470 U ES 1077470U ES 201230722 U ES201230722 U ES 201230722U ES 201230722 U ES201230722 U ES 201230722U ES 1077470 U ES1077470 U ES 1077470U
- Authority
- ES
- Spain
- Prior art keywords
- vials
- container
- translation
- machine
- materialized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126601 medicinal product Drugs 0.000 title abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 6
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 6
- 239000011780 sodium chloride Substances 0.000 claims abstract description 6
- 230000003313 weakening effect Effects 0.000 claims abstract description 4
- 230000000295 complement effect Effects 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000000420 mucociliary effect Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- RPABDKTXMKOGKI-OYTUFZPASA-N 6-methyl-n-[2-[(2s,5s,8s,11s,14s,17s,20s,23s)-8,11,14,20-tetrakis(2-aminoethyl)-5-[(1r)-1-hydroxyethyl]-17,23-bis(2-methylpropyl)-3,6,9,12,15,18,21,24-octaoxo-1,4,7,10,13,16,19,22-octazacyclotetracos-2-yl]ethyl]octanamide Chemical compound CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O RPABDKTXMKOGKI-OYTUFZPASA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960000533 dornase alfa Drugs 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
Envase para productos medicamentosos Package for medicated products
La presente invención se refiere a un envase para productos medicamentosos, específicamente para productos a base de ácido hialurónico y cloruro de sodio, previstos para la administración de aerosol en pacientes afectados por la fibrosis quística. The present invention relates to a package for medicated products, specifically for products based on hyaluronic acid and sodium chloride, intended for aerosol administration in patients affected by cystic fibrosis.
El objeto de la invención consiste en una serie de viales contenedores de respectivas dosis del producto citado, que forman un conjunto monobloque, del que son fácilmente independizados de forma unitaria. The object of the invention consists of a series of container vials of respective doses of the aforementioned product, which form a monobloc assembly, from which they are easily unitary independent.
En la fibrosis quística, el fallo de funcionamiento de la proteína del canal CFTR, asignada al intercambio iónico de Na y cloro entre la célula y el entorno extracelular, determina una reducción de la capa de líquido periciliar que reviste la mucosa respiratoria. Esta capa líquida superficial, mantenida constante respecto al agua que entra y sale de la 45 célula siguiendo el flujo de los iones de Na y Cl, es normalmente de aproximadamente 10 IM. In cystic fibrosis, the malfunction of the CFTR channel protein, assigned to the ionic exchange of Na and chlorine between the cell and the extracellular environment, determines a reduction in the layer of pericillary fluid that lines the respiratory mucosa. This surface liquid layer, kept constant with respect to the water entering and leaving the cell following the flow of the Na and Cl ions, is normally approximately 10 IM.
Esta capa acuosa superficial permite que los cilios del epitelio se muevan completamente sumergidos en la capa de líquido periciliar y desarrollen de ese modo plenamente el cometido de eliminar las secreciones y todo lo que haya sido atrapado por los mismos para la eliminación. En los sujetos afectados por FQ, la capa de líquido periciliar se 50 reduce en más del 50% llegando a ser de 4 IM, de modo que esta reducción de volumen reduce la capacidad de los cilios de moverse adecuadamente y por tanto reduce, si no llega a anular, el transporte mucociliar. This superficial aqueous layer allows the cilia of the epithelium to move completely submerged in the periciliar fluid layer and thereby fully develop the task of eliminating secretions and everything that has been trapped by them for removal. In subjects affected by CF, the pericilliary fluid layer is reduced by more than 50% to 4 IM, so that this reduction in volume reduces the ability of the cilia to move properly and therefore reduces, if not gets to cancel, mucociliary transport.
A causa de la reducción del aclaramiento mucociliar, existe un atascamiento de la mucosidad en las vías respiratorias a consecuencia de la deshidratación, una colonización bacteriana y un desarrollo de las condiciones 55 ideales para una colonización crónica por parte de la flora patógena, sobre todo la Gram-. Because of the reduction in mucociliary clearance, there is a blockage of the mucus in the airways as a result of dehydration, a bacterial colonization and a development of the ideal conditions for a chronic colonization by the pathogenic flora, especially the Gram-.
Desde hace no muchos años, la terapia sistémica ha ido acompañada de la terapia de aerosoles por ejemplo con 5 antibióticos tales como tobramicina, colimicina, ciprofloxacina, aztreonam y con mucoactivos tales como, por ejemplo, dornasa alfa, una enzima capaz de fragmentar el ADN contenido en la mucosidad reduciendo así la viscosidad. For not many years, systemic therapy has been accompanied by aerosol therapy, for example with 5 antibiotics such as tobramycin, colimycin, ciprofloxacin, aztreonam and with mucoactive agents such as, for example, dornase alfa, an enzyme capable of fragmenting DNA content in mucus thus reducing viscosity.
El envase que la invención propone ha sido especialmente concebido para contener el producto medicamentoso de que se trate, concretamente ácido hialurónico y cloruro de sodio para su aplicación al paciente en forma de aerosol por vía respiratoria. The package proposed by the invention has been specially designed to contain the medicament product in question, specifically hyaluronic acid and sodium chloride for application to the patient in the form of a respiratory spray.
De forma mas concreta el envase de la invención se materializa en un grupo de viales monodosis, solidarizados entre si con carácter monopieza, en disposición coplanaria, viales entre los que se establecen uniones frangibles para facilitar la independización de cada uno de ellos en el momento de su consumo o incorporación al dispositivo nebulizador. More specifically, the package of the invention materializes in a group of single-dose vials, sympathetic to each other with a single-piece character, in coplanar arrangement, vials between which frangible junctions are established to facilitate the independence of each of them at the time of its consumption or incorporation into the nebulizer device.
Cada vial adopta una configuración similar a la de una pequeña botella, de un material plástico apropiado, de cuyo cuerpo emergen aletas laterales para unión entre viales y cuyo cuello, a nivel de su embocadura frangible, se prolonga en otra aleta transversal, paralela a las del cuerpo, de mayor longitud, concretamente la necesaria para que los diferentes viales que configuran el envase queden también fijados entre si a través de esta zona extrema, estando los dos tipos de aletas correspondientes a los distintos viales solidarizadas entre si y con carácter frangible, para independización de los mismos, como anteriormente se ha dicho. Each vial adopts a configuration similar to that of a small bottle, of an appropriate plastic material, from whose body lateral wings emerge for union between vials and whose neck, at the level of its frangible mouth, extends into another transverse fin, parallel to the of the body, of greater length, specifically the one necessary so that the different vials that make up the container are also fixed to each other through this extreme area, the two types of fins corresponding to the different vials solidarity with each other and with frangible character, for their independence, as previously stated.
Obviamente las uniones entre aletas, en lugar de materializarse en líneas de rotura convenientemente debilitadas, pueden materializarse en cualesquiera elementos de unión desmontable que resulten apropiados. Obviously the joints between fins, instead of materializing in conveniently weakened break lines, can materialize in any removable joint elements that are appropriate.
Como también es evidente, la capacidad de cada uno de los viales citados será la adecuada a una dosis de ácido hialurónico y cloruro de sodio. As is also evident, the capacity of each of the vials cited will be adequate at a dose of hyaluronic acid and sodium chloride.
Para complementar la descripción que se está realizando y con objeto de ayudar a una mejor comprensión de las características del invento, de acuerdo con un ejemplo preferente de realización práctica del mismo, se acompaña como parte integrante de dicha descripción, un juego de dibujos en donde con carácter ilustrativo y no limitativo, se ha representado lo siguiente: To complement the description that is being made and in order to help a better understanding of the characteristics of the invention, according to a preferred example of practical implementation thereof, a set of drawings is attached as an integral part of said description. In an illustrative and non-limiting manner, the following has been represented:
La figura 1.- Muestra, según una vista general en perspectiva, un envase para productos medicamentosos realizado de acuerdo con el objeto de la presente invención, de acuerdo con un ejemplo de realización práctica en el que en el mismo participan cinco viales. Figure 1 shows, according to a general perspective view, a package for medicated products made in accordance with the object of the present invention, in accordance with an example of practical embodiment in which five vials participate in it.
La figura 2.- Muestra una vista en alzado frontal del envase de la figura anterior. Figure 2.- Shows a front elevation view of the container of the previous figure.
La figura 3.- Muestra un perfil del envase parcialmente seccionado. Figure 3.- Shows a profile of the partially sectioned container.
La figura 4.- Muestra, finalmente, una sección transversal del envase de acuerdo con la línea de corte (A-B) de la figura 2. Figure 4.- Finally shows a cross section of the package according to the cutting line (A-B) of Figure 2.
A la vista de las figuras reseñadas puede observarse como el envase para productos medicamentosos que la invención propone está constituido mediante un conjunto de cinco viales (1), cada uno de los cuales presenta un cuerpo, que se corresponde con la propia referencia (1), a modo de una diminuta botella, preferentemente de sección elíptica tal como se observa en la sección de la figura 4, con un volumen interior (2) adecuado a una dosis de ácido hialurónico y cloruro de sodio para una aplicación, mediante aerosol, en pacientes afectados por fibrosis quística, y con una pareja de aletas (3) contrapuestas, a través de las que se realiza la unión con carácter monopieza entre viales, aletas que se sitúan coplanariamente en correspondencia con eje mayor de la elipse que configura el cuerpo de cada vial. In view of the aforementioned figures, it can be seen how the package for medicated products that the invention proposes is constituted by a set of five vials (1), each of which has a body, which corresponds to the reference itself (1) , by way of a tiny bottle, preferably of an elliptical section as seen in the section of Figure 4, with an internal volume (2) suitable for a dose of hyaluronic acid and sodium chloride for an aerosol application, in patients affected by cystic fibrosis, and with a pair of opposing fins (3), through which the connection is made with a single piece between vials, fins that are coplanarly located in correspondence with the major axis of the ellipse that configures the body of each vial
Las líneas de unión (4) entre aletas (3) se materializan en líneas de debilitamiento, que facilitan la independización de cada vial en el momento de su utilización. The connecting lines (4) between fins (3) materialize in weakening lines, which facilitate the independence of each vial at the time of its use.
Cada vial (1) está además dotado de otra aleta (5), transversal, situada sobre su embocadura y de mayor longitud, de manera que estas aletas extremas (5) están todas ellas unidas entre si también con carácter monopieza mediante las líneas de debilitamiento (4’) que facilitan la independización de los viales, y que además facilitan también la apertura en su momento de cada uno de ellos. Each vial (1) is also provided with another transverse fin (5), located on its mouth and of greater length, so that these extreme fins (5) are all joined together also with a single piece character by means of the weakening lines (4 ') that facilitate the independence of the vials, and that also facilitate the opening at the time of each of them.
Se obtiene de esta manera un envase múltiple, en el que un número determinado de viales forman un conjunto monopieza, sustancialmente aplanado, fácilmente alojable por ejemplo en el seno de una caja de cartón o cualquier otro tipo de contenedor apropiado, del que dichos viales resultan fácilmente extraíbles de forma unitaria, en el momento de aplicación de la respectiva dosis de producto contra la fibrosis quística. A multiple container is thus obtained, in which a certain number of vials form a substantially flat, single-piece assembly, easily accommodated, for example, in a cardboard box or any other appropriate type of container, from which said vials result easily removable unitary, at the time of application of the respective dose of product against cystic fibrosis.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201230722U ES1077470Y (en) | 2012-07-02 | 2012-07-02 | PACKAGING FOR MEDICINAL PRODUCTS. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201230722U ES1077470Y (en) | 2012-07-02 | 2012-07-02 | PACKAGING FOR MEDICINAL PRODUCTS. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES1077470U true ES1077470U (en) | 2012-07-25 |
| ES1077470Y ES1077470Y (en) | 2012-10-24 |
Family
ID=46458647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201230722U Expired - Fee Related ES1077470Y (en) | 2012-07-02 | 2012-07-02 | PACKAGING FOR MEDICINAL PRODUCTS. |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES1077470Y (en) |
-
2012
- 2012-07-02 ES ES201230722U patent/ES1077470Y/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES1077470Y (en) | 2012-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2243523T3 (en) | DISTRIBUTION VALVE FOR NASAL SPRAYING. | |
| BR112015007285A2 (en) | medication dispensing device | |
| ES2600204T3 (en) | Unidirectional Valve Assembly | |
| BR112014008551A2 (en) | valve set for use with liquid container and medicine bottle | |
| AR075870A1 (en) | COMPLETELY STABILIZED EXCAVATOR TOOTH SETTING | |
| EP3057575A1 (en) | Preservative free pharmaceutical compositions for ophthalmic administration | |
| BR112013011591A2 (en) | device for applying a medicine and methods to improve pain | |
| ES2333619T3 (en) | MEDICINAL CAPSULES FOR INHALATION. | |
| CN103052419A (en) | nasal spray device | |
| US20080228162A1 (en) | Single-use ampoule | |
| ES2611677T3 (en) | Procedure for marking a vial, vial so marked | |
| BR112015006225A2 (en) | fire spray set | |
| ES1077470U (en) | Container for medicinal products. (Machine-translation by Google Translate, not legally binding) | |
| ITMO20090012A1 (en) | CONTAINER FOR FLUID PRODUCTS, PARTICULARLY PHARMACEUTICAL, COSMETIC, MEDICAL OR SIMILAR PRODUCTS | |
| Kimbell et al. | Nasal steroid spray simulations using measured spray characteristics in healthy and rhinitic nasal passages | |
| ES2652298T3 (en) | Implant device for access to the sinuses and kit | |
| PT837662E (en) | FIT FOR SOUTIEN | |
| ITBO20090132A1 (en) | DEVICE FOR NEBULIZATION OF SUBSTANCES IN A VENTILATION CIRCUIT | |
| ES2936259T3 (en) | Device for single-dose containers | |
| CN217865745U (en) | Medicine dispensing bag | |
| MotolESE et al. | caSo clinico di un corpo eStraneo corneale con diagnoSi e ManageMent conServativo a lungo terMine | |
| ES2837066T3 (en) | Eye drop applicator | |
| ES1073777U (en) | On improved monodosis for medicines (Machine-translation by Google Translate, not legally binding) | |
| BR202016014841U2 (en) | NOZZLE TYPE NASAL HYGIENIZATION PLUG | |
| BR202016002843U2 (en) | NASAL HEALING TOILET |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG1K | Utility model granted |
Effective date: 20121011 |
|
| PC1K | Transfer of utility model |
Owner name: CHIESI FARMACEUTICI S.P.A. Effective date: 20140114 |
|
| FD1K | Utility model lapsed |
Effective date: 20220727 |